Literature DB >> 29447438

Serum uric acid is associated with incidence of heart failure with preserved ejection fraction and cardiovascular events in patients with arterial hypertension.

Jun Gu1, Yu-Qi Fan1, Hui-Li Zhang1, Jun-Feng Zhang1, Chang-Qian Wang1.   

Abstract

The objective of the present study was to evaluate clinical implications of serum uric acid (UA) on the progression of heart failure with preserved ejection fraction (HFpEF) in hypertensive patients. A total of 1009 adult patients with left ventricular hypertrophy and suspected left ventricular diastolic dysfunction were enrolled at our hospital from January 2008 to December 2011. With a median follow-up of 7.2 years, 136 (13.2%) patients developed new-onset HFpEF and 151 (15.0%) had major adverse cardiovascular events (MACEs). Compared with the lowest UA tertile of UA (<302 μmol L-1 ), subjects in the highest tertile (>367 μmol L-1 ) had a higher risk of developing new-onset HFpEF (HR: 1.761, 95% CI: 1.119-2.772, P = .015) as well as MACEs (HR: 1.664, 95% CI: 1.086-2.547, P = .019). Our findings indicate that hyperuricemia is associated with detrimental effects in terms of the incidence of new-onset HFpEF as well as MACEs in hypertensive patient. ©2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  diastolic dysfunction; heart failure with preserved ejection fraction; hypertension; left ventricular hypertrophy; uric acid

Mesh:

Substances:

Year:  2018        PMID: 29447438      PMCID: PMC8031219          DOI: 10.1111/jch.13210

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  41 in total

1.  Long-term prescription of beta-blocker delays the progression of heart failure with preserved ejection fraction in patients with hypertension: A retrospective observational cohort study.

Authors:  Jun Gu; Yu-Qi Fan; Ling Bian; Hui-Li Zhang; Zuo-Jun Xu; Yang Zhang; Qi-Zhi Chen; Zhao-Fang Yin; Yu-Shui Xie; Chang-Qian Wang
Journal:  Eur J Prev Cardiol       Date:  2016-02-25       Impact factor: 7.804

2.  Fatigability, Exercise Intolerance, and Abnormal Skeletal Muscle Energetics in Heart Failure.

Authors:  Kilian Weiss; Michael Schär; Gurusher S Panjrath; Yi Zhang; Kavita Sharma; Paul A Bottomley; Asieh Golozar; Angela Steinberg; Gary Gerstenblith; Stuart D Russell; Robert G Weiss
Journal:  Circ Heart Fail       Date:  2017-07       Impact factor: 8.790

3.  Prevalence of Hyperuricemia in Patients With Acute Heart Failure With Either Reduced or Preserved Ejection Fraction.

Authors:  Alberto Palazzuoli; Gaetano Ruocco; Oreste De Vivo; Ranuccio Nuti; Peter A McCullough
Journal:  Am J Cardiol       Date:  2017-07-17       Impact factor: 2.778

4.  Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging.

Authors:  Stefan D Anker; Wolfram Doehner; Mathias Rauchhaus; Rakesh Sharma; Darrel Francis; Christoph Knosalla; Constantinos H Davos; Mariantonietta Cicoira; Waqar Shamim; Michel Kemp; Robert Segal; Karl Josef Osterziel; Francisco Leyva; Roland Hetzer; Piotr Ponikowski; Andrew J S Coats
Journal:  Circulation       Date:  2003-04-21       Impact factor: 29.690

5.  The effect of xanthine oxidase inhibition upon ejection fraction in heart failure patients: La Plata Study.

Authors:  Horacio E Cingolani; Juan A Plastino; Eduardo M Escudero; Brian Mangal; Joanne Brown; Néstor G Pérez
Journal:  J Card Fail       Date:  2006-09       Impact factor: 5.712

6.  Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study.

Authors:  Joshua M Hare; Brian Mangal; Joanne Brown; Charles Fisher; Ronald Freudenberger; Wilson S Colucci; Douglas L Mann; Peter Liu; Michael M Givertz; Richard P Schwarz
Journal:  J Am Coll Cardiol       Date:  2008-06-17       Impact factor: 24.094

7.  Association between long-term prescription of aldosterone antagonist and the progression of heart failure with preserved ejection fraction in hypertensive patients.

Authors:  Jun Gu; Yu-Qi Fan; Zhi-Hua Han; Li Fan; Ling Bian; Hui-Li Zhang; Zuo-Jun Xu; Zhao-Fang Yin; Yu-Shui Xie; Jun-Feng Zhang; Chang-Qian Wang
Journal:  Int J Cardiol       Date:  2016-06-25       Impact factor: 4.164

8.  Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction.

Authors:  Kalkidan Bishu; Anita Deswal; Horng H Chen; Martin M LeWinter; Gregory D Lewis; Marc J Semigran; Barry A Borlaug; Steven McNulty; Adrian F Hernandez; Eugene Braunwald; Margaret M Redfield
Journal:  Am Heart J       Date:  2012-10-16       Impact factor: 4.749

9.  Prevention of the development of heart failure with preserved ejection fraction by the phosphodiesterase-5A inhibitor vardenafil in rats with type 2 diabetes.

Authors:  Csaba Mátyás; Balázs T Németh; Attila Oláh; Marianna Török; Mihály Ruppert; Dalma Kellermayer; Bálint A Barta; Gábor Szabó; Gábor Kökény; Eszter M Horváth; Beáta Bódi; Zoltán Papp; Béla Merkely; Tamás Radovits
Journal:  Eur J Heart Fail       Date:  2016-12-19       Impact factor: 15.534

10.  Serum uric acid is associated with incidence of heart failure with preserved ejection fraction and cardiovascular events in patients with arterial hypertension.

Authors:  Jun Gu; Yu-Qi Fan; Hui-Li Zhang; Jun-Feng Zhang; Chang-Qian Wang
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-02-15       Impact factor: 3.738

View more
  6 in total

Review 1.  Hyperuricemia and Hypertension: Links and Risks.

Authors:  Douglas J Stewart; Valerie Langlois; Damien Noone
Journal:  Integr Blood Press Control       Date:  2019-12-24

Review 2.  The role of arterial hypertension in development heart failure with preserved ejection fraction: just a risk factor or something more?

Authors:  Marijana Tadic; Cesare Cuspidi; Athanasios Frydas; Guido Grassi
Journal:  Heart Fail Rev       Date:  2018-09       Impact factor: 4.214

3.  Impact of plasma xanthine oxidoreductase activity in patients with heart failure with preserved ejection fraction.

Authors:  Ken Watanabe; Tetsu Watanabe; Yoichiro Otaki; Tetsuro Shishido; Takayo Murase; Takashi Nakamura; Shigehiko Kato; Harutoshi Tamura; Satoshi Nishiyama; Hiroki Takahashi; Takanori Arimoto; Masafumi Watanabe
Journal:  ESC Heart Fail       Date:  2020-05-20

Review 4.  Hyperuricemia and the Risk of Heart Failure: Pathophysiology and Therapeutic Implications.

Authors:  Ke Si; Chijing Wei; Lili Xu; Yue Zhou; Wenshan Lv; Bingzi Dong; Zhongchao Wang; Yajing Huang; Yangang Wang; Ying Chen
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-12       Impact factor: 5.555

5.  Serum uric acid is associated with incidence of heart failure with preserved ejection fraction and cardiovascular events in patients with arterial hypertension.

Authors:  Jun Gu; Yu-Qi Fan; Hui-Li Zhang; Jun-Feng Zhang; Chang-Qian Wang
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-02-15       Impact factor: 3.738

6.  Prognostic impact of HbA1c variability on long-term outcomes in patients with heart failure and type 2 diabetes mellitus.

Authors:  Jun Gu; Jian-An Pan; Yu-Qi Fan; Hui-Li Zhang; Jun-Feng Zhang; Chang-Qian Wang
Journal:  Cardiovasc Diabetol       Date:  2018-06-30       Impact factor: 9.951

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.